
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Click the title above to open the Pharmaceutical Executive March 2016 issue in an interactive PDF format.
over 10 years ago
Beyond 2020: Building Strategic Coherence in the New Health Economyover 10 years ago
What Errors Do We Miss in Clinical Trials?over 10 years ago
Data Disclosure: Sealing the Error Envelopeover 10 years ago
Vaccines 2016: Big Bets for Global Threatsover 10 years ago
Drug Delivery Roundtable: More than the Pillover 10 years ago
Orphans of the Stormover 10 years ago
Country Report: The Netherlands




